Clinical validation in liquid biopsy of a genetic and epigenetic firm as a prognostic tool in the face of chemoimmunotherapy in patients with lung cancer.

Treatment with neoadjuvant chemotherapy plus immunotherapy (CH-I) is of key importance for the treatment of patients with locally advanced and metastatic NMSC. However, we lack biomarkers capable of discriminating between patients who benefit from the CH-I combination and those who do not.

The main objective of the project is to obtain a new tool for stratifying the risk of relapse/progression in patients with microcytic lung cancer treated with chemoimmunotherapy using new molecular biomarkers.

Lung cancer

It is the second most frequently diagnosed tumor in men and women


The great success of immunotherapy in the metastatic environment has aroused great interest in exploring the effectiveness of immunotherapy in earlier stages

Funded through the call for public-private collaboration of the State Plan for Scientific, Technical and Innovation Research 2021-2023, within the framework of the Recovery, Transformation and Resilience Plan and by the European Union nextGenerationEU / PRTR

To achieve the objectives

CPP2022-009545 2023-2026

Consortium with: IDIPHISA – Lung Cancer Research Group (Dr. Mariano Provencio) and Liquid Biopsy Unit (Dr. Atocha Romero) and Tumor Microenvironment group (Dr. Alberto Cruz); IdiPAZ – Group of Experimental Therapies and New Cancer Biomarkers (Dra. Ibáñez de Cáceres)


Proyectos relacionados



Desarrollo de marcadores moleculares para identificar los largos supervivientes con inmunoterapia

Read more


Caracterización inmunológica y molecular de pacientes de cáncer de pulmón para inmunoterapia

Read more